Consultancy: AstraZeneca, Bayer, Boehringer Ingelheim, Fresenius Medical Care, Novo Nordisk, and Vifor Fresenius Medical Care Renal Pharma Grant/research support: Boehringer Ingelheim, Canadian Institutes Health Research, European Union, Idorsia, Novo Nordisk, Sandoz, and Sano Speaker bureaus: AstraZeneca, B. Braun, Fresenius Medical Care, Novartis, Novo Nordisk, and Roche Tara I. Chang, MD, MS, is an associate professor of medicine, division chief, and director of clinical research in the Division of Nephrology at Stanford University School of Medicine in Palo Alto, CA, USA. She received her medi- cal degree at the University of Michigan before completing her internal medi- cine residency at the University of Cal- ifornia, San Francisco, CA, USA, and her nephrology fellowship at Stanford. Dr. Chang maintains an active clin- ical research program that focuses on improving cardio- vascular outcomes among patients with CKD. Dr. Chang s research projects involve clinical epidemiology and clinical trials. She recently served as a US national leader for the Canagli ozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial. Dr. Chang is a member of the KDIGO Executive Committee and is actively involved with the American Society of Nephrology and the US National Kidney Foundation. Her other re- sponsibilities include serving as an associate editor for the American Heart Journal, and as a member of the editorial boards of Kidney360, the Clinical Journal of the American Society of Nephrology, and the Journal of Human Hypertension. 